157 related articles for article (PubMed ID: 15592834)
1. Endometrial K-ras mutations in postmenopausal breast cancer patients treated with adjuvant tamoxifen or toremifene.
Wallén M; Tomás E; Visakorpi T; Holli K; Mäenpää J
Cancer Chemother Pharmacol; 2005 Apr; 55(4):343-346. PubMed ID: 15592834
[TBL] [Abstract][Full Text] [Related]
2. K-ras mutation in the endometrium of tamoxifen-treated breast cancer patients, with a comparison of tamoxifen and toremifene.
Hachisuga T; Tsujioka H; Horiuchi S; Udou T; Emoto M; Kawarabayashi T
Br J Cancer; 2005 Mar; 92(6):1098-103. PubMed ID: 15756272
[TBL] [Abstract][Full Text] [Related]
3. Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women.
Marttunen MB; Cacciatore B; Hietanen P; Pyrhönen S; Tiitinen A; Wahlström T; Ylikorkala O
Br J Cancer; 2001 Apr; 84(7):897-902. PubMed ID: 11286468
[TBL] [Abstract][Full Text] [Related]
4. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients.
Tomás E; Kauppila A; Blanco G; Apaja-Sarkkinen M; Laatikainen T
Gynecol Oncol; 1995 Nov; 59(2):261-6. PubMed ID: 7590484
[TBL] [Abstract][Full Text] [Related]
5. Monitoring of endometrial K-ras mutation in tamoxifen-treated patients with breast cancer.
Tsujioka H; Hachisuga T; Fukuoka M; Ueda T; Miyahara D; Horiuchi S; Shirota K; Yoshizato T; Emoto M; Miyamoto S; Kawarabayashi T
Int J Gynecol Cancer; 2009 Aug; 19(6):1052-6. PubMed ID: 19820367
[TBL] [Abstract][Full Text] [Related]
6. Toremifene as a substitute for adjuvant tamoxifen in breast cancer patients.
Bertelli G; Queirolo P; Vecchio S; Angiolini C; Bergaglio M; Del Mastro L; Signorini A; Valenzano M; Venturini M
Anticancer Res; 2000; 20(5C):3659-61. PubMed ID: 11268435
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group.
Holli K; Valavaara R; Blanco G; Kataja V; Hietanen P; Flander M; Pukkala E; Joensuu H
J Clin Oncol; 2000 Oct; 18(20):3487-94. PubMed ID: 11032589
[TBL] [Abstract][Full Text] [Related]
8. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients.
Cheng WF; Lin HH; Torng PL; Huang SC
Gynecol Oncol; 1997 Aug; 66(2):233-7. PubMed ID: 9264568
[TBL] [Abstract][Full Text] [Related]
9. [Clinicopathological features of endometrial carcinoma in tamoxifen- and toremifene-treated breast cancer patients].
Otsuka I; Takahashi S; O'uchi K; Akimoto N; Hanari K; Ogaki Y; Enatsu YH; Takigawa A; Takaya H; Tanaka A; Kaseki H; Yamada T
Gan To Kagaku Ryoho; 2010 Feb; 37(2):279-83. PubMed ID: 20154485
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy.
Buzdar AU; Hortobagyi GN
J Clin Oncol; 1998 Jan; 16(1):348-53. PubMed ID: 9440763
[TBL] [Abstract][Full Text] [Related]
11. Toremifene in postmenopausal breast cancer. Efficacy, safety and cost.
Mäenpää JU; Ala-Fossi SL
Drugs Aging; 1997 Oct; 11(4):261-70. PubMed ID: 9342556
[TBL] [Abstract][Full Text] [Related]
12. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients.
Marttunen MB; Hietanen P; Tiitinen A; Ylikorkala O
J Clin Endocrinol Metab; 1998 Apr; 83(4):1158-62. PubMed ID: 9543133
[TBL] [Abstract][Full Text] [Related]
13. Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials.
Zhou WB; Ding Q; Chen L; Liu XA; Wang S
Breast Cancer Res Treat; 2011 Aug; 128(3):625-31. PubMed ID: 21553116
[TBL] [Abstract][Full Text] [Related]
14. Long-term "protective" effect of aromatase inhibitors on the endometrium of postmenopausal breast cancer patients.
Markovitch O; Tepper R; Fishman A; Aviram R; Cohen I
Breast Cancer Res Treat; 2009 Jan; 113(2):321-6. PubMed ID: 18297393
[TBL] [Abstract][Full Text] [Related]
15. Evolving role of toremifene in the adjuvant setting.
Holli K
Oncology (Williston Park); 1997 May; 11(5 Suppl 4):48-51. PubMed ID: 9165507
[TBL] [Abstract][Full Text] [Related]
16. Endometrial evaluation in postmenopausal breast cancer patients receiving tamoxifen: an ultrasound, color flow Doppler, hysteroscopic and histological study.
Exacoustos C; Zupi E; Cangi B; Chiaretti M; Arduini D; Romanini C
Ultrasound Obstet Gynecol; 1995 Dec; 6(6):435-42. PubMed ID: 8903921
[TBL] [Abstract][Full Text] [Related]
17. High-dose toremifene vs tamoxifen in postmenopausal advanced breast cancer.
Gershanovich M; Hayes DF; Ellmén J; Vuorinen J
Oncology (Williston Park); 1997 May; 11(5 Suppl 4):29-36. PubMed ID: 9165504
[TBL] [Abstract][Full Text] [Related]
18. Uterine changes during tamoxifen, toremifene, and other therapy for breast cancer: evaluation with magnetic resonance imaging.
Ochi J; Hayakawa K; Moriguchi Y; Urata Y; Yamamoto A; Kawai K
Jpn J Radiol; 2010 Jul; 28(6):430-6. PubMed ID: 20661693
[TBL] [Abstract][Full Text] [Related]
19. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer.
Saarto T; Blomqvist C; Ehnholm C; Taskinen MR; Elomaa I
J Clin Oncol; 1996 Feb; 14(2):429-33. PubMed ID: 8636753
[TBL] [Abstract][Full Text] [Related]
20. Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen.
Mourits MJ; Van der Zee AG; Willemse PH; Ten Hoor KA; Hollema H; De Vries EG
Gynecol Oncol; 1999 Apr; 73(1):21-6. PubMed ID: 10094875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
